{"disease":{"id":"nfe2l2-gene-mutation","name":"nfe2l2 gene mutation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04265534","title":"KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":40,"lead_sponsor_name":"Calithera Biosciences, Inc","has_results":false},{"nct_id":"NCT04698681","title":"NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial","phase":"","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Calithera Biosciences, Inc","has_results":false},{"nct_id":"NCT05275673","title":"A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Faeth Therapeutics","has_results":true}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}